Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The Drone Video of the Year is stunning – you've not seen Namibia like this - 2How to get tickets to Jay-Z’s sold out Yankee Stadium shows
- 3Famous Versatile Brands: Your Decision
- 4Study casts doubt on potential for life on Jupiter's moon Europa
- 5Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery?
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Creative Do-It-Yourself Ventures for Each Expertise Level
- Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
- German foreign minister backs abandoning EU's unanimity principle
- 1,000-mile Saharan dust storm, from the sky and from the ground
- Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution
